Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-09T05:41:47.919Z Has data issue: false hasContentIssue false

19 - Vaccine toxicology: nonclinical predictive strategies

from II - INTEGRATED APPROACHES OF PREDICTIVE TOXICOLOGY

Published online by Cambridge University Press:  06 December 2010

By
Sarah Gould  and
Raymond Oomen
Edited by
Jinghai J. Xu  and
Laszlo Urban
Jinghai J. Xu
Affiliation:
Merck Research Laboratory, New Jersey
Laszlo Urban
Affiliation:
Novartis Institutes for Biomedical Research, Massachusetts
Get access

Summary

INTRODUCTION

Vaccines are one of the safest and most effective preventative treatments against infectious diseases. The first vaccine was against smallpox, and developed by Edward Jenner (1796) as a simple preparation of crude vaccinia. Today's vaccines are composed of a diverse range of products, which may include live attenuated or inactivated bacteria, virus or parasites, living irradiated cells, crude fractions or purified parts of microorganisms, polysaccharides, toxoids, recombinant proteins/polypeptides, and vector-based and DNA vaccines. Formulations may include novel adjuvants, excipients, and multiple antigen combinations and be delivered by novel routes via viral vectors or new delivery systems. Vaccines also offer wider possibilities with the promise of therapeutic benefit against various disorders such as cancer, prevention or treatment of immune-mediated diseases, and antismoking therapy.

Vaccines have an exemplary safety record, with a benefit that is immeasurable. With today's risk-averse society and heightened awareness, vaccine safety attracts intense scrutiny, particularly in the case of preventative vaccines, which are given to healthy adults, infants, and children. The safety benefit ratio is skewed heavily toward safety and as many infectious diseases are not prevalent today, many people may not perceive the benefit. In fact, in recent years, there has been a shift toward a risk benefit for the individual, and as a result of certain alleged safety issues, there has been a reduction in vaccinations, (e.g., Japan and DTP vaccines, MMR in UK, polio in African regions); this will ultimately lead to decreased herd immunity, and the prevalence of certain diseases may return.

Type
Chapter
Information
Predictive Toxicology in Drug Safety , pp. 344 - 370
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bonnet, MC, Targaglia, J, Verdier, F, Kourilsky, P, Lindberg, A, Klein, M, Moingeon, P. Recombinant viruses as a tool for therapeutic vaccination against human cancers. Immunol Lett. 2000;74:11–25.CrossRefGoogle ScholarPubMed
Brennan, FR, Dougan, D. Non-clinical safety evaluation of novel vaccines and adjuvants: New products, new strategies. Vaccine. 2005;23:3210–3222.CrossRefGoogle ScholarPubMed
Dempster, AM, Haworth, R. Pre-clinical safety evaluation of viral vaccines. In: Cavagnaro JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. John Wiley & Sons Inc. Hoboken, New Jersey. 2008;31:683–712.Google Scholar
Sela, M. and Hilleman, MR. Therapeutic vaccines: Realities of today and hopes for tomorrow. PNAS, 2004;101(2):14559.CrossRefGoogle ScholarPubMed
Chin, J, Magoffin, RL, Shearer, , Schieble, JH, Lenette, EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89:449–463.CrossRefGoogle Scholar
Kim, HW, Canchola, JG, Brandt, CD, Pyles, G, Chanock, R, Jensen, K, Parrott, RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.CrossRefGoogle ScholarPubMed
Grayston, JT, Foy, HM, Kenny, ER. The epidemiology of mycoplasma infections of the human respiratory tract. In: Hayflick, L, ed. The Mycoplasmatales and the L-Phase of Bacteria Amsterdam, The Netherlands: Appelton-Century-Crofts 1969: 651.
Stewart, GT. Toxicity of pertussis vaccine: Frequency and probability of reactions. J Epidemiol Community Health. 1979;33:150–156.CrossRefGoogle ScholarPubMed
Murphy, TV, Gargiullo, PM, Massoudi, MS, Nelson, DB, Jumaan, AO, Okoro, C, Zanardi, LR, Setia, S, Fair, E, LeBaron, CW, Wharton, M, Livingood, J. Intussusception among infacts given an oral rotavirus vaccine. For the rotavirus intussuception investigation team. N Eng J Med. 2001;344(8):564–572.CrossRefGoogle Scholar
O'Hagan, DT, Rappuoli, R. Novel approaches to vaccine delivery. Pharma Res. 2004;21(9):1519–1530.CrossRefGoogle ScholarPubMed
Bonhoeffer, J, Heininger, U. Adverse events following immunization: perception and evidence. Curr Opin Infect. 2007;20;237–246.CrossRefGoogle ScholarPubMed
Sutkowski, EM, Gruber, MF. Non Clinical safety evaluation of preventative vaccines-regulatory considerations, Business briefing. Future Drug Discov. 3rd edition. 2003;34–37.Google Scholar
Verdier, F. Non-clinical vaccine safety assessment. Toxicology. 2002:174;37–43.CrossRefGoogle ScholarPubMed
Olsen, H, Betton, G, Robinson, D, Thomas, K, Monro, A, Kolaja, G, Lilly, P, Sanders, J, Sipes, G, Bracken, W, Dorato, M, Duen, K, Smith, P, Berger, B, Heller, A.Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32:56–67.CrossRefGoogle Scholar
,EMEA. Note for guidance on preclinical pharmacological and toxicological testing of vaccines. CPMP/SWP/465/95. 1997.
,WHO. Guidelines on nonclinical evaluation vaccines. Technical report series No. 927. 2005.
,FDA CBER. Guidance for industry: considerations for reproductive toxicity studies for preventative vaccines for infectious disease indications. Draft guidance. 2006.
,OECD. Principles on Good Laboratory Practice (as revised in 1997).
Viret, JF, Favre, GD. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine. 2004;22:2457–2469.CrossRefGoogle ScholarPubMed
Schalk, J, Mooi, FR, Berbers, G, Aerts, L, Ovelgonne, H, Kimman, TG.Preclinical and clinical safety studies on DNA vaccines. Human Vaccines. 2006;2(2):45–53.CrossRefGoogle ScholarPubMed
Kumar, PU, Kumar, D, Annapurnav, V, Kirshna, P, Kalyansundaram, S, Suresh, P, Harishankar, N, Jagadeesan, V, Hariahran, S, Naidu, N, Krishnaswamy, K, Rangarajan, PN, Srinivasan, VA, Reddy, GS, Sesikeran, B. Nonclinical toxicology study of recombinant – Plasmid DNA anti-rabies vaccines. Vaccine. 2006;24:2790–2798.CrossRefGoogle ScholarPubMed
Lebron, JA, Wolf, JJ, Kaplanski, CV, Ledwith, BJ. Ensuring the quality, potency and safety of vaccines during preclinical development. Vaccine. 2005;4(6): 855–866.Google ScholarPubMed
Laan, JW, Forstor, R, Ledwith, B, Gruber, M, Gould, S, Penninks, A. Non clinical testing of vaccines: Report from a workshop. Drug Inf J. 2009;43:75–85.Google Scholar
Subramanyam, M, Rinaldi, N, Mertssching, E, Hutto, D. Selection of relevant species. (In: Cavagnaro, JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. John Wiley & Sons Inc. Hoboken, New Jersey.; 2008;9:181–206.
Kantor, J, Irvine, K, Abrams, S, Snoy, P, Olsen, R, Greiner, J, Kaufman, H, Eggensperger, D, Schlom, J. (1992). Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 1992;52:6917–6925.Google Scholar
Tang, RS, Spaete, RR, Thompson, MW, MacPhail, M, Guzzetta, JM, Ryan, PC, Reisinger, K, Chandler, P, Hilty, M, Walker, RE, Gomez, MM, Losonsky, GA. Development of a PIV-vectored RSV vaccine: Preclinical evaluation of safety, toxicity and enhanced disease and initial clinical testing in healthy adults. Vaccine. 2008;26: 373–6382.CrossRefGoogle ScholarPubMed
Pasetti, MF, Levine, MM, Sztein, MB. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine. 2003;21:401–418.CrossRefGoogle ScholarPubMed
Woods, AM, Wang, WW, Shaw, DM, Ward, CM, Carroll, MW, Rees, B, Stern, PI. Characterization of the murine 5T4 oncofoetal antigen: A target for immunotherapy in cancer. Biochem. J. 2002;366:353–365.CrossRefGoogle Scholar
Gerdts, V, Littel-van, Hurk, S, Drunen, Griebel, PJ, Babiuk, . Use of animal models in the development of human vaccine sFuture Microbiol. 2007;2(6): 667–675.CrossRefGoogle Scholar
Glueck, R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine. 2002;20:S42–244.CrossRefGoogle Scholar
Lang, D. Safety evaluation of toxin adjuvants delivered intranasally. Meeting notes. National Institute of Allergy and Infectious Diseases. 2001.
Thuilliez, C, Dorso, L, Howroyd, P, Gould, S, Chanut, F, Burnett, R. (2008). Histopathological lesions following intramuscular administration of saline in laboratory rodents and rabbits. Exp Toxicol Pathol. 2008;61:13–21.CrossRefGoogle ScholarPubMed
Gruber, MF. Maternal immunization: US FDA regulatory considerations. Vaccine. 2003;21:3487–3491.CrossRefGoogle ScholarPubMed
Verdier, F, Barrow, P, Burge, J. Reproductive toxicity testing of vaccines. Toxicology. 2003;85:213–219.CrossRefGoogle Scholar
Amstey, MS, Gall, SA. Smallpox vaccine and pregnancy. Obstet Gynecol. 2002;100:87–93.Google Scholar
Weinbauer, GF, Frings, W, Fuchs, A, Niehaus, M, Osterburg, I. Reproductive/development toxicity assessment of biopharmaceuticals in non human primates In: Cavagnaro, JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. John Wiley & Sons Inc. Hoboken, New Jersey. 2008;18:379–397.Google Scholar
Holsapple, MP, West, LJ, Landreth, KS. Species comparison of anatomical and functional immune system development. Birth Defects Res. (Part B). 2003;68:321–334.CrossRefGoogle ScholarPubMed
,ICH7A. Harmonised tripartite guideline on safety pharmacology studies for human pharmaceuticals. S7A, Step 4. 2000.Google Scholar
Turner, JR, Durham, TA. Nonclinical Development Integrated Cardiac Safety: Assessment Methodologies for Non-cardiac Drugs in Discovery, Development, and Postmarketing Surveillance. John Wiley & Sons Inc. Hoboken, New Jersey. 2009:111–134.Google Scholar
,FDA CBER. Draft guidance for industry: Considerations for plasmid DNA vaccines for infectious disease indications. 2007.
Ledwith, BJ, Manam, S, Troilo, PJ, Barnum, AB, Pauley, CJ, Griffiths, TG, Harper, LB, Schock, HB, Zhang, H, Faris, JE, Way, PA, Beare, CM, Bagdon, WJ, Nichols, WW. Plasmid DNA vaccines: Assay for integration into host genomic DNA. Dev Biol (Basel). 2000;104:33–43.Google ScholarPubMed
Wang, Z, Troilo, PJ, Griffiths II, TGPacchione, SJ, Barnum, AB, Harper, LB, Pauley, CJ, Nui, Z, Denisova, L, Follmer, TT, Rizzuto, G, Ciliberto, G, Fattori, E, Monica, NL, Manam, S, Ledwith, BJ. Detection of integration of plasmid DNA into host genomic DNA following intramuscular and electroporation. Gene Therapy. 2004;11: 711–721.CrossRefGoogle ScholarPubMed
Siegrist, CA. Neonatal and early life vaccinology. Vaccine. 2001;19:3331–3346.CrossRefGoogle ScholarPubMed
Marthas, M, Rompay, KV, Earl, P, Tartaglia, J. Conference on Retroviruses and Opportunistic Infections. Program Abstr Conf Retrovir Oppor Infect 11th 2004 San Franc Calif. 2004 Feb 8–11; 11: abstract no. 271.
Silverstein, AM, Segal, S. The ontogeny of antigen-specific T cells. J Exp Med. 1975;142(3):802–804.CrossRefGoogle ScholarPubMed
Mor, G, Yamshchikov, G, Sedegah, M. Induction of neonatal tolerance by plasmid DNA vaccination of mice. J. Clin.Invest. 1996;98:2700–2705.CrossRefGoogle Scholar
Samarkos, M, Vaiopoulos, G. The role of infections in the pathogenesis of autoimmune diseases. Inflammation and allergy. 2005;4:99–103.Google ScholarPubMed
Deodhar, SD. Autoimmune diseases: overview and current concepts of pathologenesis. Clin Biochem. 1992;25(3):181–185.CrossRefGoogle Scholar
Marshall, E. A shadow falls on hepatitis B vaccination effort. Science. 1998; 281(5377):630–631.CrossRefGoogle ScholarPubMed
Dickman, S. (Possible cause found for Lyme arthritis. Science. 1998;281(5377): 631–632.CrossRefGoogle ScholarPubMed
Shoenfeld, Y, Aron-Maor, A. Vaccination and autoimmunity – “vaccinosis” A dangerous liaison?J Autoimmun. 2000;14:1–10.Google ScholarPubMed
Monteyne, P, André, FE. Is there a causal link between hepatitis B vaccination and multiple sclerosis?Vaccine. 2000;18:1994–2001.CrossRefGoogle Scholar
Brickman, CM, Shoenfeld, Y. The mosaic of autoimmunity. Scand J Clin Lab Invest Suppl. 2001;235:3–15.Google ScholarPubMed
Chen, RT, Pless, R, Destefano, F. Epidemiology of autoimmune reactions induced by vaccination. J. Autoimmun. 2001;16:309–318.CrossRefGoogle ScholarPubMed
Wraith, DC, Goldman, M, Lambert, PH. Vaccination and autoimmune disease: what is the evidence?Lancet. 2003;362 (9396): 1659–1666.CrossRefGoogle ScholarPubMed
Tsuchiya, N, Williams, RC. Molecular mimicry- hypothesis or reality?West J Med. 1992;157:133–138.Google ScholarPubMed
Christen, U, Herrath, MGInfections and autoimmunity – good or bad?J. Immunol. 2005;174(12):7481–7486.CrossRefGoogle ScholarPubMed
Ang, CW, Jacobs, BC, Laman, JD. The Guillain-Barré syndrome: A true case of molecular mimicry. Trends Immunol. 2004;25(2):61–66.CrossRefGoogle ScholarPubMed
Guilherme, L, Oshiro, SE, Fae, KC, Cunha-Neto, E, Renesto, G, Goldberg, AC, Tanaka, AC, Pomerantzeff, PM, Kiss, MH, Silva, C, Guzman, F, Patarroyo, ME, Southwood, S, Sette, A, Kalil, J.T-cell reactivity against streptococcal antigens in the periphery mirrors reactivity of heart-infiltrating T lymphocytes in rheumatic heart disease patients. Infect Immun. 2001;69:5345–5351.CrossRefGoogle ScholarPubMed
Burova, , Nagornev, VA, Pigarevky, PV, Gladilina, MM, Gavrilova, EA, Seliverstova, VG, Totolian, AA, Thern, A, Shalen, C. Myocardial tissue damage in rabbits injected with group A streptococci, types M1 and M22. Role of bacterial immunoglobulin G-binding surface proteins. Acta Pathol Microbiol Immunol Scand. 2004;113(1):21–30.CrossRefGoogle Scholar
Yuki, N, Susuki, K, Koga, M, Nishimoto, Y, Odaka, M, Hirata, K, Taguchi, K, Miyatake, T, Furukawa, K, Kobata, T, Yamada, M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA. 2004;101(31):11404–11409. Epub 2004 Jul 26.CrossRefGoogle ScholarPubMed
Yuki, N.Campylobacter sialyltransferase gene polymorphism directs clinical features of Guillain-Barré syndrome. J Neurochem. 2007;103(Suppl 1):150–158.CrossRefGoogle ScholarPubMed
Dinkla, K, Nitsche-Schmitz, DP, Barroso, V, Reissmann, S, Johansson, HM, Frick, IM, Rohde, M, Chhatwal, GS. Identification of a streptococcal octapeptide motif involved in acute rheumatic fever. J Biol Chem. 2007;282(26):18686–18693. Epub Apr 23.CrossRefGoogle ScholarPubMed
Dinkla, K, Talay, SR, Mörgelin, M, Graham, RM, Rohde, M, Nitsche-Schmitz, DP, Chhatwal, GS. Crucial role of the CB3-region of collagen IV in PARF-induced acute rheumatic fever. PLoS One. 2009;4(3):e4666. Epub Mar 2.CrossRefGoogle ScholarPubMed
Gross, DM, Forsthuber, T, Tary-Lehmann, M, Etling, C, Ito, K, Nagy, ZA, Field, JA, Steere, AC, Huber, BT.Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998;281(5377):703–706.CrossRefGoogle ScholarPubMed
Abbott, A.Lyme disease: Uphill struggle. Nature. 2006;439 (7076):524–525.CrossRefGoogle ScholarPubMed
Ball, R, Shadomy, SV, Meyer, A, Huber, BT, Leffell, MS, Zachary, A, Belotto, M, Hilton, E, Bryant-Genevier, M, Schriefer, ME, Miller, FW, Braun, MM. HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination. Arthritis Rheum. 2009;60(4):1179–1186.CrossRefGoogle ScholarPubMed
Vyas, NK, Vyas, MN, Chervenak, MC, Bundle, DR, Pinto, BM, Quiocho, FA. Structural basis of peptide-carbohydrate mimicry in an antibody-combining site. Proc Natl Acad Sci USA. 2003;100(25):15023–15028.CrossRefGoogle Scholar
Donnelly, JJ, Ulmer, JB, Shiver, JW, Liu, MA. DNA vaccines. Annu Rev Immunol. 1997;15:617–648.CrossRefGoogle ScholarPubMed
Gurunathan, S, Klinman, DM, Seder, RA. DNA vaccines: Immunology, application and optimization. Annu Rev Immunol. 2000;18:927–974.CrossRefGoogle Scholar
Krieg, AM.CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709–760.CrossRefGoogle ScholarPubMed
,FAO/WHO. Evaluation of allergenicity of genetically modified foods. Report of a joint FAO/WHO expert consultation on allergenicity of foods derived from bio­technology. (Food and Agriculture Organization of the United Nations (FAO), Rome, 2001. http://www.who.int/foodsafety/publications/biotech/en/ec_jan2001.pdf. 2001.
,FAO/WHO. Codex Alimentarius Commission. Alinorm 03/34: Joint FAO/WHO Food Standard Programme, Codex Alimentarius Commission, Twenty-Fifth Session, Rome, 30 June–5 July, 2003. Appendix III, Guideline for the conduct of food safety assessment of foods derived from recombinant-DNA plants and Appendix IV, Annex on the assessment of possible allergenicity, 2003:47–60.
Aalberse, RC.Structural biology of allergens. J Allergy Clin Immunol. 2000;106(2):228–238.CrossRefGoogle ScholarPubMed
Ladics, GS, Bannon, GA, Silvanovich, A, Cressman, RF.Comparison of conventional FASTA identity searches with the 80 amino acid sliding window FASTA search for the elucidation of potential identities to known allergens. Mol Nutr Food Res. 2007;51(8):985–998.CrossRefGoogle ScholarPubMed
Silvanovich, A, Nemeth, MA, Song, P, Herman, R, Tagliani, L, Bannon, GA. The value of short amino acid sequence matches for prediction of protein allergenicity. Toxicol Sci. 2006;90(1):252–258.CrossRefGoogle ScholarPubMed
Goodman, RE, Vieths, S, Sampson, HA, Hill, D, Ebisawa, M, Taylor, SL, Ree, R.Allergenicity assessment of genetically modified crops – What makes sense?Nat Biotechnol. 2008;26(1):73–81.CrossRefGoogle ScholarPubMed
Zhang, Q, Wang, P, Kim, Y, Haste-Andersen, P, Beaver, J, Bourne, PE, Bui, HH, Buus, S, Frankild, S, Greenbaum, J, Lund, O, Lundegaard, C, Nielsen, M, Ponomarenko, J, Sette, A, Zhu, Z, Peters, B. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res. 2008;36:W513–W518. Epub 2008 May 31.CrossRefGoogle Scholar
Taneja, V, David, CS.Lessons from animal models for human autoimmune diseases. Nat Immunol. 2001;2(9),781–784.CrossRefGoogle ScholarPubMed
Classen, JB.The timing of immunization affects the development of diabetes in rodents. Autoimmunity. 1996;24(3):137–145.CrossRefGoogle ScholarPubMed
Ravel, G, Christ, M, Liberge, P, Burnett, R, Descotes, J. Effects of two pediatric vaccines on autoimmune diabetes in NOD female mice. Toxicol Lett. 2003;146:93–100.CrossRefGoogle ScholarPubMed
Ravel, G, Christ, M, Howard, F, Descotes, J.Autoimmunity, environmental exposure and vaccination; Is there a link?Toxicology. 2004;196:211–216.CrossRefGoogle Scholar
Descotes, J, Ravel, G, Ruat, C.Vaccines: Predicting the risk of allergy and autoimmunity. Toxicology. 2002;174:45–51.CrossRefGoogle ScholarPubMed
Bohlke, K, Davis, RL, Marcy, SM, Braun, MM. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112:815–820.CrossRefGoogle ScholarPubMed
Fulginiti, VA, Eller, JJ, Downie, AW, Kempe, CH.Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccine. J Am Med Assoc. 1967;202 (12):1075–1080.CrossRefGoogle Scholar
Graham, BS, Henderson, GS, Tang, YW, Lu, X, Neuzil, KM, Colley, DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993;151(4):2032–2040.Google Scholar
Waris, ME, Tsou, C, Erdman, DD, Zaki, SR,Anderson, LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol. 1996;70(5):2852–2860.Google ScholarPubMed
Prince, GA, Jenson, AB, Hemming, VG, Murphy, BR, Walsh, EE, Horswood, RL, Chanock, R. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin inactivated virus. J Virol. 1986;57(3):721–728.Google Scholar
Prince, GA, Curtis, SJ, Yim, KC, Porter, DD. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol. 2001;82:2881–2888.CrossRefGoogle ScholarPubMed
Moghaddam, A, Olszewska, W, Wang, B, Tregoning, JS, Helson, R, Sattentau, QJ, Openshaw, PJ. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med. 2006;12(8):905–907.CrossRefGoogle ScholarPubMed
Igietseme, JU, Ananaba, GA, Bolie, J, Bowers, S, Moore, T, Belay, T, Eko, FO,Lyn, D, Black, CM. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol. 2000;164:4212–4219.CrossRefGoogle ScholarPubMed
Openshaw, P, Culley, FJ, Olszewska, W. Immunopathogenesis vaccine-enhanced RSV disease. Vaccine. 2001;20:S27–S31.CrossRefGoogle ScholarPubMed
Opensahw, PJ, Tregoning, JS. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev. 2005;18(3):541–555.CrossRefGoogle Scholar
Swart, LT, Kuiken, T, Timmerman, HH, Amerongen, G, Van, Hoogen, B, Vos, HW, Neijens, HJ, Andeweg, AC, Osterhaus, A. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13 associated hypersensitivity to subsequent RSV infection. J Virol. 2002;76(22):11561–11569.CrossRefGoogle ScholarPubMed
Ruat, C, Caillet, C, Bidaut, A, Simon, J, Osterhaus, A. Vaccination of macaques with adjuvanted formalin – invactivated influenza A virus (HRN1) vaccines: Protection against HRN1 challenge without disease enhancement. J Virol. 2008;82(5):2565–2569.CrossRefGoogle Scholar
Perreau, M, Pantaleo, G, Kremer, EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med. 2008;12:2717–2725.CrossRefGoogle Scholar
Byrd, LG, Prince, GA. Animal models of respiratory syncytial virus infection. Clin Infect Dis. 1997;25:1363–1368.CrossRefGoogle ScholarPubMed
Medjitna, T, Stadier, C, Bruckner, L, Griot, C, Ottiger, HP. DNA vaccines: Safety aspect assessment and regulation. Dev Biol. 2006;126 (Discussion 327):261–270.Google ScholarPubMed
Verdier, F, Burnett, R, Michelet-Habchi, C, Moretto, P, Fievet-Groyne, F, Sauzeat, E. Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine. 2005;23:1359–1367.CrossRefGoogle ScholarPubMed
,EMEA. Guideline on adjuvants in vaccines for human use. EMEA/CHMP/VEG/134716/2004. 2005.
Verdier, F, Patriarca, C, Descotes, J. Autoantibodies in conventional toxicity testing. Toxicology. 1997;119(1):51–58.CrossRefGoogle ScholarPubMed
Shoenfeld, Y, Isenberg, D. The mosaic of autoimmunity. In: Turk, JL, ed. Research Monographs in Immunology. Amsterdam: Elsevier; 1989: 1–52.Google Scholar
Randolph, GJ, Beaulieu, S, Lebecque, S, Steinman, RM, Muller, WA. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science. 1998;282: 480–483.CrossRefGoogle Scholar
Simister, N.Placental transport of immunoglobulin G. Vaccine. 2003;24: 3365–3369.CrossRefGoogle Scholar
Fujimoto, K, Terao, K, Cho, F, Honjo, S. The placental transfer of IgG in the cynomologus monkey. Jpn J Med Sci Biol. 1993;36:171–176.CrossRefGoogle Scholar
Rojas, R, Apodaca, G. Immunoglobulin transport across polarized epithelial cells. Nat Rev Mol Cell Biol. 2002;3:1–12.CrossRefGoogle ScholarPubMed
Appleby, P, Catty, D.Transmission of immunoglobulin to foetal and neonatal mice. J Reproductive Immunol. 1983;5:203–213.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×